Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

    NEXT STORY
    Global Medical Devices Market Report 2019-2022 – A $521+ Billion Opportunity Analysis
    PREV STORY
    HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in Paris
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Myriad Announces New GeneSight® Study Published in Personalized Medicine

    Study based upon OptumInsight data showed More Than $6,200 in First Year Healthcare Costs ...

    author_avatar
    NASDAQ Market News

    argenx reports third quarter 2017 financial results and provides business update

    October 26, 2017 Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ...

    author_avatar
    NASDAQ Market News

    Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.

    DUBLIN, Ireland, June 23, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) (Horizon), a ...

    author_avatar
    NASDAQ Market News